Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.
about
Early phase clinical trials to identify optimal dosing and safetyDesigns of drug-combination phase I trials in oncology: a systematic review of the literatureStatistical controversies in clinical research: requiem for the 3 + 3 design for phase I trialsTowards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.Dose finding with longitudinal data: simpler models, richer outcomes.Innovations for phase I dose-finding designs in pediatric oncology clinical trials.Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid TumoursPhase 1 trial design: is 3 + 3 the best?Adaptive phase I/II clinical trials for drug combination assessment in oncology using the outcomes of each cycle.An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials.Challenges and Innovations in Phase I Dose-Finding Designs for Molecularly Targeted Agents and Cancer Immunotherapies.Multivariate Markov models for the conditional probability of toxicity in phase II trials.Adaptive Phase I clinical trial design using Markov models for conditional probability of toxicity.A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials.
P2860
Q26865076-1853BE85-4435-48FE-83C8-C4105D7F5379Q26996348-51169404-4AD8-4546-9BDA-B1DEFD020453Q27023178-AC358CE4-8F00-4B9E-B85E-2AF4371AC532Q30968729-E782DF29-F784-40FD-83C0-9015C0F630F6Q30976631-2521FEDD-8CF5-4056-8C5D-8B8E6C63304EQ36757843-4F300334-1138-4909-BBA0-A2D7A19F28DBQ37000818-23FF413D-458F-4722-8248-BB1F2B04B654Q38222466-374BB9D0-1DB1-4D60-83D3-0195FCE28BA1Q38608632-1D07F057-FE9F-430C-8B4D-BC1BF5F1CFB3Q38735192-437CDE4A-D5F9-4848-AC64-9FEC41079AEAQ39374749-2BF471BE-A9C8-4FFE-9B3A-7F114B4BC844Q40650639-37F0A64D-BF57-46C6-8928-A2F68373F405Q40811925-E4EA7C86-6E94-43DA-9157-3F7D9932887CQ42697628-40777809-1913-4B93-877D-B53E5EBDDFE3
P2860
Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Dose-finding design using mixe ...... se I oncology clinical trials.
@ast
Dose-finding design using mixe ...... se I oncology clinical trials.
@en
type
label
Dose-finding design using mixe ...... se I oncology clinical trials.
@ast
Dose-finding design using mixe ...... se I oncology clinical trials.
@en
prefLabel
Dose-finding design using mixe ...... se I oncology clinical trials.
@ast
Dose-finding design using mixe ...... se I oncology clinical trials.
@en
P2860
P356
P1476
Dose-finding design using mixe ...... ase I oncology clinical trials
@en
P2093
Rodolphe Thiébaut
P2860
P304
P356
10.1002/SIM.5960
P407
P577
2013-09-10T00:00:00Z